Barclays’s TherapeuticsMD TXMD Stock Holding History

Barclays’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-240	Closed	-$86K	–	6939
2017 Q1	$86K	Buy	+240	New	+$74.3K	﹤0.01%	4998

Other funds holding TXMD

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays's TXMD Position: Q3 2026 in Review

Barclays reduced its TherapeuticsMD (TXMD) stake by 86% in Q3 2026, selling an estimated $40 and leaving 3 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #5231.

Barclays first reported a position in TXMD in Q2 2013 and has held it in 37 quarters since. The position peaked at $698K in Q4 2015. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2026.

Barclays held 3 shares of TherapeuticsMD worth $6 as of Q3 2026.
Barclays sold 19 TherapeuticsMD shares in Q3 2026, an estimated $40.
TherapeuticsMD made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5231 holding.
Barclays first reported a position in TherapeuticsMD in Q2 2013 and has held it in 37 quarters since.
Barclays's TherapeuticsMD position peaked at $698K in Q4 2015.
36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.